Narrowing price gap may not make Roche's Lucentis more attractive than Eylea
This article was originally published in Scrip
Roche has cut the price of of its ophthalmology drug Lucentis so that its cost compared more closely with the newly approved and marketed competitor, Eylea from Regeneron. But analysts feel that the less frequent dosing of Eylea is more important to patient and physician acceptability than cost. What will really sway the decision between the two drugs is the eagerly anticipated data from a head to head comparisons between treatments.